The U.S. National Cancer Institute is working with Dell, Terascala and the Translational Genomics Research Institute to bolster its pediatric oncology research capabilities. The NCI ultimately hopes to use the new computing capabilities to discover new biomarkers and therapeutic targets for childhood cancers.
The study aims to recruit 40 people in the United Kingdom to wear watch-sized sensors on their belts. By placing the sensors around the body's center of mass the team from Imperial College London hope to gather data on each individual's position and walking speed.
Mayo Clinic and IBM have teamed up to apply cutting-edge technology to the age-old problem of enrolling patients into clinical trials. Starting next year Mayo Clinic will use IBM's supercomputer Watson to automatically match patients to clinical trials.
Illumina has laid the groundwork for increased use of next-generation sequencing in clinical research by striking a deal with Big Pharma, which could result in the company disrupting diagnostics using its dominance in NGS.
Intel has spent the past year adding tools for gathering and analyzing data, notably by taking a stake in Cloudera and buying Basis. And the strategy now has a major test case, with the Michael J. Fox Foundation teaming up with Intel to remotely monitor people with Parkinson's disease.
A Wall Street Journal feature this week on researchers' long-standing concerns about the consequences of patients talking about clinical trials online digs into how biopharma companies are tapping technology to counter concerns about unblinding and manipulating inclusion/exclusion criteria.
While virtual biotechs and the service providers that support them have been around for years, Transcriptic and rival West Coast startups think they can improve the model through automation. And having raised cash from Google's venture unit and struck deals with some elite academic centers, Transcriptic is now rolling out the next phase of its plan.
This week a German team presented data from a database analysis study that found a link between a diabetes drug and a slight dip in the risk of developing Alzheimer's.
If the Michigan-based company--which describes itself as "Match.com for clinical trials"--achieves its goal, it will have doubled the number of top-5 companies on its books.
While PhRMA, EFPIA and other trade groups have established positions on trial data transparency, Big Pharma consortium TransCelerate BioPharma has been on the periphery of the public debate. Behind the scenes though it has been looking into the best way to redact information--and has shared its thoughts on the topic with the European Medicines Agency (EMA).